Knut J Olanders1, Gerd A E Lundgren2, Anders M G Johansson2. 1. Department of Intensive- and Perioperative Care, Lund University Hospital, S-221 85 Lund, Sweden. Electronic address: knut.olanders@skane.se. 2. Department of Intensive- and Perioperative Care, Lund University Hospital, S-221 85 Lund, Sweden.
Abstract
STUDY OBJECTIVE: To investigate whether betamethasone decreases the incidence of postoperative nausea/vomiting (PONV) and reduces postoperative pain following partial mastectomy. DESIGN: Prospective randomized, double-blinded study. SETTING:Operating room and Postanesthesia Care Unit of a university hospital. PATIENTS: 80 ASA physical status 1 and 2 women scheduled for elective breast cancer surgery. INTERVENTIONS: Patients were randomly allocated to two groups in double-blinded fashion: Group B (betamethasone; 37 pts) and Group C (control; 38 pts). Group B received 8 mg of betamethasone intravenously before the start of surgery. MEASUREMENTS: The rate of PONV and pain were recorded using a numeric rating scale (NRS; 0-10), as well as rescue doses of antiemetics (ondansetron) and analgesics (ketobemidone). MAIN RESULTS: There was a significant lower incidence of postoperative nausea (PON) scoring NRS ≥ 1 in Group B in the 4 to 12-hour period compared with Group C (P = 0.02). The cumulative incidence of PON was 57% in Group B versus 68% in Group C (P = 0.27). The overall incidence of postoperative vomiting (POV) was 18% and 20% in Groups B and C, respectively. Postoperative pain was reduced by 40% in Group B in the 4 to 12-hour period, but the mean dose of postoperative rescue analgesic did not differ between the groups. CONCLUSIONS:Preoperative betamethasone reduces the severity of PONV and pain in patients undergoing elective breast surgery.
RCT Entities:
STUDY OBJECTIVE: To investigate whether betamethasone decreases the incidence of postoperative nausea/vomiting (PONV) and reduces postoperative pain following partial mastectomy. DESIGN: Prospective randomized, double-blinded study. SETTING: Operating room and Postanesthesia Care Unit of a university hospital. PATIENTS: 80 ASA physical status 1 and 2 women scheduled for elective breast cancer surgery. INTERVENTIONS:Patients were randomly allocated to two groups in double-blinded fashion: Group B (betamethasone; 37 pts) and Group C (control; 38 pts). Group B received 8 mg of betamethasone intravenously before the start of surgery. MEASUREMENTS: The rate of PONV and pain were recorded using a numeric rating scale (NRS; 0-10), as well as rescue doses of antiemetics (ondansetron) and analgesics (ketobemidone). MAIN RESULTS: There was a significant lower incidence of postoperative nausea (PON) scoring NRS ≥ 1 in Group B in the 4 to 12-hour period compared with Group C (P = 0.02). The cumulative incidence of PON was 57% in Group B versus 68% in Group C (P = 0.27). The overall incidence of postoperative vomiting (POV) was 18% and 20% in Groups B and C, respectively. Postoperative pain was reduced by 40% in Group B in the 4 to 12-hour period, but the mean dose of postoperative rescue analgesic did not differ between the groups. CONCLUSIONS: Preoperative betamethasone reduces the severity of PONV and pain in patients undergoing elective breast surgery.
Authors: Jorge Jiménez-Tornero; Ana Olivia Cortés-Flores; Mariana Chávez-Tostado; Gilberto Morgan-Villela; Carlos Zuloaga-Fernández Del Valle; Raymundo Zuloaga-Fernández Del Valle; Luis Alberto García-González; Vanesa Sarahí Fernández-Avalos; Roberto Carlos Miranda-Ackerman; Andrea Socorro Alvarez-Villaseñor; Gabriela Ambriz-González; Francisco José Barbosa-Camacho; Clotilde Fuentes-Orozco; Vianca Seleste Contreras-Cordero; Alejandro González-Ojeda Journal: Gland Surg Date: 2020-10
Authors: Stephanie Weibel; Gerta Rücker; Leopold Hj Eberhart; Nathan L Pace; Hannah M Hartl; Olivia L Jordan; Debora Mayer; Manuel Riemer; Maximilian S Schaefer; Diana Raj; Insa Backhaus; Antonia Helf; Tobias Schlesinger; Peter Kienbaum; Peter Kranke Journal: Cochrane Database Syst Rev Date: 2020-10-19
Authors: Sofie Björner; Ann H Rosendahl; Maria Simonsson; Andrea Markkula; Karin Jirström; Signe Borgquist; Carsten Rose; Christian Ingvar; Helena Jernström Journal: Front Endocrinol (Lausanne) Date: 2017-11-28 Impact factor: 5.555